Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678077 | 0.88 | ALOX5 (0.56) | MAPK14ALOX5OPRD1PTGS2EP300 | |
| SCHEMBL7761536 | 0.86 | OPRD1 (0.48) | ALOX5OPRD1PTGS2EP300MEN1 | |
| SCHEMBL14195275 | 0.83 | ALOX5 (0.51) | MAPK14ALOX5OPRD1PTGS2EP300 | |
| SCHEMBL7756777 | 0.80 | OPRD1 (0.52) | ALOX5OPRD1PTGS2EP300ALDH1A1 | |
| SCHEMBL7756786 | 0.75 | OPRD1 (0.47) | MAPK14ALOX5OPRD1PTGS2EP300 | |
| SCHEMBL5599629 | 0.71 | OPRD1 (0.53) | MAPK14OPRD1EP300MEN1ALDH1A1 | |
| SCHEMBL7760704 | 0.70 | OPRD1 (0.49) | ALOX5OPRD1EP300MEN1ALDH1A1 | |
| SCHEMBL7899189 | 0.69 | OPRD1 (0.51) | MAPK14OPRD1EP300MEN1ALDH1A1 | |
| SCHEMBL7902764 | 0.67 | OPRD1 (0.54) | MAPK14OPRD1PTGS2EP300ALDH1A1 | |
| SCHEMBL8985349 | 0.66 | PTGS2 (0.62) | PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | MAPK14 3329/4885ALOX5 25/4885OPRD1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.